Instil Bio, Inc. is an innovative clinical-stage biopharmaceutical company based in Dallas, Texas, specializing in advanced cell therapies to revolutionize cancer treatment. The company’s proprietary tumor-infiltrating lymphocyte (TIL) therapies aim to bolster the immune response against a range of cancer types, showcasing a commitment to personalized immunotherapy. With a strong pipeline focused on addressing critical unmet needs in oncology, Instil Bio holds the potential to significantly enhance patient outcomes and transform the paradigm of cancer care. Show more

Location: 3963 MAPLE AVENUE, DALLAS, TX, UNITED STATES, 75219, Dallas, TX, 75219, USA | Website: https://instilbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

47.88M

52 Wk Range

$5.67 - $42.79

Previous Close

$7.06

Open

$6.96

Volume

74,500

Day Range

$6.96 - $7.44

Enterprise Value

53.13M

Cash

5.801M

Avg Qtr Burn

-10.56M

Insider Ownership

6.29%

Institutional Own.

67.91%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ITIL-306 Details Cancer, Non-small cell lung carcinoma, Ovarian cancer, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ITIL-168 Details Cancer, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXN-2510/IMM2510 + chemotherapy Details Non-small cell lung carcinoma (NSCLC)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AXN-2510 (formerly SYN-2510) /IMM2510 Details Relapsed/Refractory Solid Tumors	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.